<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145128</url>
  </required_header>
  <id_info>
    <org_study_id>AG881-C-008</org_study_id>
    <nct_id>NCT04145128</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants</brief_title>
  <official_title>A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agios Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agios Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics (PK) and safety of AG-881 in
      healthy Japanese and Non-Asian participants after single oral doses of 10 mg and 50 mg of
      AG-881.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">December 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUC0-last) of AG881</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-∞) of AG881</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance Following Extravascular Dosing (CL/F) of AG881</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration Observed (Cmax) of AG881</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2) of AG881</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Plasma Concentration (tmax) of AG881</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of AG881</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 504 hours) after each administration of AG-881</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Changes in Clinical Laboratory Tests from Screening to 22 days in Period 1 and 2</measure>
    <time_frame>Screening (Day -1) up to 22 days in Period 1 and 2 (Each Period is 22 days)</time_frame>
    <description>Clinical laboratory assessments will include hematology, blood chemistry, and urinalysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Changes in Physical Examinations from Screening to 22 days in Period 1 and 2</measure>
    <time_frame>Screening (Day -1) up to 22 days in Period 1 and 2 (Each Period is 22 days)</time_frame>
    <description>Physical examination will include, examination of skin, neurological, respiratory, cardiovascular, and gastrointestinal systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Changes in Vital Sign Measurements from Screening to 22 days in Period 1 and 2</measure>
    <time_frame>Screening (Day -1) up to 22 days in Period 1 and 2 (Each Period is 22 days)</time_frame>
    <description>Vital sign measurements will include body temperature, respiratory rate, blood pressure, and heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Changes in Electrocardiograms (ECGs) from Screening to 22 days in Period 1 and 2</measure>
    <time_frame>Screening (Day -1) up to 22 days in Period 1 and 2 (Each Period is 22 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 28 days after last dose of AG-881 (Up to 71 days)</time_frame>
    <description>An AE is any untoward medical occurrence associated with the use of a drug, whether or not considered drug-related.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Concomitant Medications</measure>
    <time_frame>Up to 28 days after last dose of AG-881 (Up to 71 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AG-881</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive AG-881 10 mg, tablet orally, once in Period 1 followed by AG-881 50 mg, tablet orally, once in Period 2. Period 1 and Period 2 will be separated by a washout period of 20 days between doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG881</intervention_name>
    <description>AG-881 tablets.</description>
    <arm_group_label>AG-881</arm_group_label>
    <other_name>Vorasidenib</other_name>
    <other_name>AGI 23088</other_name>
    <other_name>AGI 0023088</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have provided voluntary written informed consent.

          2. Adult male or female, 18 to 55 years of age, inclusive, at Screening.

          3. Continuous nonsmoker who has not used nicotine containing products for at least 3
             months prior to the first dosing and throughout the study.

          4. Have a body mass index (BMI) of ≥ 18.0 and ≤ 32.0 kg/m^2 at Screening.

          5. Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs, or ECG. Liver function tests (serum
             alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase
             [ALP], and bilirubin [total and direct]) must be ≤ the upper limit of normal (ULN).

          6. Female participants must be of nonchildbearing potential defined as a female who has
             undergone one of the following sterilization procedures at least 6 months prior to the
             first dosing: hysteroscopic sterilization; bilateral tubal ligation or bilateral
             salpingectomy; hysterectomy; bilateral oophorectomy. Or is postmenopausal with
             amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating
             hormone (FSH) serum levels consistent with postmenopausal status.

          7. A nonvasectomized, male participant must agree to use a condom with spermicide or
             abstain from sexual intercourse during the study until 90 days after the last dosing.
             (No restrictions are required for a vasectomized male provided his vasectomy has been
             performed 4 months or more prior to the first dosing of study drug. A male who has
             been vasectomized less than 4 months prior to study first dosing must follow the same
             restrictions as a nonvasectomized male).

          8. Male participants must agree not to donate sperm from the first dosing until 90 days
             after the last dosing.

          9. Understands the study procedures in the informed consent form (ICF), and be willing
             and able to comply with the protocol.

         10. Additional Criteria for Japanese participants only: be first-generation Japanese,
             defined as meeting all of the following conditions: born in Japan; has 2 Japanese
             biological parents and 4 Japanese biological grandparents; has lived outside of Japan
             for &lt;5 years; has made no significant changes in lifestyle, including diet, since
             leaving Japan.

         11. Additional Criteria for Non-Asian participants only: Non-Asian participants will have
             2 biological parents and 4 biological grandparents of Non-Asian descent.

        Exclusion Criteria:

          1. Mentally or legally incapacitated or has significant emotional problems at the time of
             the Screening visit or expected during the conduct of the study.

          2. History or presence of clinically significant medical or psychiatric condition or
             disease in the opinion of the Investigator or designee.

          3. History of any illness that, in the opinion of the Investigator or designee, might
             confound the results of the study or pose an additional risk to the participant (eg,
             history or presence of rashes) by their participation in the study.

          4. History of stomach or intestinal surgery that would potentially alter
             absorption/secretion; or any major surgical procedure within the previous 3 months
             prior to Screening.

          5. History of severe and/or uncontrolled ventricular arrhythmias, or other factors that
             increase the risk of QT prolongation or arrhythmic events (eg, heart failure,
             hypokalemia, family history of long QT interval syndrome).

          6. History or presence of alcoholism or drug abuse within the past 2 years prior to the
             first dosing.

          7. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs
             or related compounds.

          8. Any positive responses on the Columbia-Suicide Severity Rating Scale (C-SSRS).

          9. Female participants of childbearing potential.

         10. Female participants with a positive pregnancy test or who are lactating.

         11. Positive urine drug or alcohol results at Screening or Day -1/Day 21.

         12. Positive results at Screening for human immunodeficiency virus (HIV) antibodies,
             hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibodies.

         13. QTcF interval is &gt;450 msec, or QRS interval &gt;110 msec, or PR interval &gt;220 msec, or
             participants who have ECG findings deemed abnormal with clinical significance by the
             Investigator or designee at Screening.

         14. Supine blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at
             Screening.

         15. Supine heart rate is lower than 40 beats per minute (bpm) or higher than 99 bpm at
             Screening.

         16. Estimated creatinine clearance &lt;90 mL/min at Screening.

         17. Unable to refrain from or anticipates the use of: any drug, including prescription and
             non-prescription medications, herbal remedies, and vitamin supplements, beginning 14
             days prior to the first dosing and throughout the study. After first dosing,
             acetaminophen (&lt;2 g per 24 hour) may be administered at the discretion of Investigator
             or designee. Hormone replacement therapy will not be allowed; any drugs known to be
             strong inducers of CYP3A, CYP2C9, or CYP2C19 enzymes including St. John's Wort and/or,
             gastric acid reducing agents (eg, protonpump inhibitors, H2-receptor antagonists,
             antacids) for 28 days, or drugs that can prolong the QT interval for 28 days, prior to
             the first dosing and throughout the study. Appropriate sources (eg, Flockhart TableTM)
             will be consulted to confirm lack of PK/Pharmacodynamic (PD) interaction with study
             drug.

         18. Refuses to abstain from alcohol from 48 hours prior to the first dosing and throughout
             the study.

         19. Refuses to abstain from grapefruit-containing foods or beverages or Seville orange
             containing foods or beverages from 14 days prior to the first dosing and throughout
             the study.

         20. Donation of blood or significant blood loss within 56 days prior to the first dose.

         21. Plasma donation within 7 days prior to the first dose.

         22. Receipt of blood or blood products within 2 months prior to the first dose.

         23. Participation in another clinical study within 30 days prior to the first dose. The
             30-day window will be derived from the date of the last blood collection or dosing,
             whichever is later, in the previous study to Day 1 of Period 1 of the current study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Chair</role>
    <affiliation>Agios Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT GLobal</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic study</keyword>
  <keyword>AG-881</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

